Paper Details

  1. Home
  2. Paper Details

Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials.

Author: GoksenYazel, LeeJong Woo, MuYi, RosnerBernard, SarkisRani A

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study analyzes the terms used to refer to cognitive and fatigue-related side effects in phase III add-on clinical trials of anti-epileptic drugs (AEDs). The findings indicate a significant dose-response effect for most AEDs, suggesting that physicians should consider aiming for lower drug loads to improve tolerability.
Paper Details　
Original Abstract of the Article :
We aimed to investigate the terms used to refer to cognitive and fatigue related side effects and their prevalence in phase III add-on clinical trials of anti-epileptic drugs (AEDs). We extracted data from publicly available FDA documents as well as the published literature. Target drug doses were t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00415-018-8971-z

データ提供：米国国立医学図書館（NLM）

Cognitive Side Effects of Anti-Epileptic Drugs: Navigating the Trade-Offs

Anti-epileptic drugs (AEDs) are crucial for managing epilepsy, but they can also have cognitive and fatigue-related side effects. This analysis investigated the prevalence and characteristics of these side effects in phase III add-on clinical trials of AEDs. The authors extracted data from publicly available FDA documents and the published literature, analyzing the terms used to describe cognitive and fatigue side effects and assessing their prevalence and dose-response relationships.

A Comprehensive Look at AED Side Effects

The analysis revealed significant variability in the terminology used to describe cognitive side effects, highlighting the need for standardized reporting practices. The authors found a clear dose-response effect for most AEDs, with higher drug loads significantly increasing the odds of developing cognitive or fatigue side effects. The study also found a wide range of placebo rates for these side effects, suggesting the importance of considering placebo effects when interpreting trial results.

Balancing Effectiveness and Tolerability in Epilepsy Treatment

As a neurologist, I recognize the challenges of managing epilepsy and the importance of balancing effectiveness with tolerability. This study provides valuable insights into the cognitive and fatigue side effects of AEDs, emphasizing the need for careful dose management and monitoring for these potential side effects. It's a reminder that finding the optimal balance between seizure control and tolerability is a critical aspect of epilepsy care. This study is like a guidepost in the desert, helping us navigate the complex landscape of epilepsy treatment and find the most effective and tolerable solutions for our patients.

Dr.Camel's Conclusion

This analysis underscores the importance of understanding the potential side effects of AEDs, particularly cognitive and fatigue-related issues. It emphasizes the need for careful dose management and thorough monitoring to optimize treatment outcomes while minimizing the impact of these side effects on quality of life. It's a reminder that the journey towards effective epilepsy treatment requires a nuanced approach, considering both the benefits and the potential drawbacks of available therapies.

Date :
  1. Date Completed 2019-06-19
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

30003357

DOI: Digital Object Identifier

10.1007/s00415-018-8971-z

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.